Xeris Biopharma Holdings Inc
NASDAQ:XERS
Net Margin
Xeris Biopharma Holdings Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Xeris Biopharma Holdings Inc
NASDAQ:XERS
|
646.3m USD |
-27%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
824.9B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
211.5B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
189B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.2B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.6B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.7B EUR |
14%
|
Xeris Biopharma Holdings Inc
Glance View
Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Xeris Biopharma Holdings Inc's most recent financial statements, the company has Net Margin of -27%.
You don't have any saved screeners yet